PRESS-RELEASE filed Aug 10, 2026 at 16:01 ET
Olema Oncology's Q2 2026 net loss widened to $63.2M (vs $43.8M a year ago) on higher R&D and G&A spending, but cash of $461.1M is ample to fund operations. The key catalyst is the completion of enrollment in the Phase 3 OPERA-01 trial, with top-line data now expected in Q1 2027, a de-risking milestone that brings the company closer to potential commercial launch. The Bayer collaboration for OP-3136 in prostate cancer also adds pipeline optionality, though the stock remains pre-revenue and binary on clinical outcomes.